Nav: Home

Sylentis presents new results on its ophthalmological compounds at ARVO 2018

April 26, 2018

  • The Company presents the preclinical and clinical results from studies of three molecules for the treatment of dry eye syndrome, macular degeneration and eye allergies.

  • The presentation will take place in the framework of the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). That will be held from the 29th of April to the 3rd of May in Honolulu, Hawaii.

Madrid, April 26th, 2018. Sylentis, Pharmaceutical Company belonging to PharmaMar Group will present new results on three ophthalmological compounds for the treatment of dry eye syndrome, macular degeneration associated to age, administered topically, and also for the treatment of eye allergies. The mentioned presentations will take place under the framework of the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) that will be held from the 29th of April up to the 3rd of May in Honolulu, Hawaii.

It comprises of various sessions, to where approximately 11,000 researchers and ophthalmologists attend every year to share the latest research developments in the field of ophthalmology, and which will contribute to a progress in the knowledge of both basic science and cutting edge treatments.

According to Ana Isabel Jiménez, Director of R&D at Sylentis, "we are proud to present our results to the first rate audience that is attending this meeting. We trust in our technology to become a real alternative for the treatment of millions of people that suffer from these types of illnesses in the future."

In fact, Jiménez highlights that "currently, the line of work where we have progressed fastest is in ophthalmology, for the treatment of illnesses such as dry eye syndrome, allergies and retinal diseases."

Sylentis, expert in the research of new treatments for ophthalmological and inflammatory illnesses, is a company leader in RNAi technology and it is one of the few companies in Europe that apply this technology to the field of ophthalmology.
The studies presented during this congress are available at

Studies to be presented by Sylentis at ARVO 2018:
  • Tivanisiran, a new treatment for Dry Eye Disease, that improved signs and symptoms in clinical trials (Posterboard number: 925 - B0103) Session: 29th April from 15:15 to 17:00 hours. Lead author: Ana Isabel Jiménez et al. R&D, Sylentis, Spain.
  • Topical administration of siRNA targeting NRARP as a new treatment for choroidal neovascularization (Posterboard Number: 2634 - A0139) Session: 1st of May from 8:15 to 10:00 hours. Lead author: Verónica Ruz, et al. Regulatory Affairs, Sylentis, Spain.
  • Development of a RNAi therapeutic for the treatment of allergic conjunctivitis (Posterboard Number: 5567 - A0259) Session: 3rd May, from 8:15 to 10:00 hours. Lead author: Victoria González et al. Clinical Department, Sylentis, Spain.

What is RNA interference?

About Sylentis

Sylentis, a company of PharmaMar (MSE:PHM), is a biotechnology company fully owned that develops innovative therapies harnessing the technology of post-transcriptional gene silencing or RNA interference (RNAi). Sylentis has developed an approach to efficiently design RNAi-based therapeutics that can be used to silence numerous disease-causing genes. We currently have a robust therapeutic program in ophthalmology with two candidates under development in Phase II and III studies for glaucoma (bamosiran) and ocular pain (SYL1001) , respectively. Sylentis is also developing new products for the treatment of several eye diseases such as ocular allergies and retina diseases. To know more about us, please visit us at


Related Macular Degeneration Articles:

Levodopa may improve vision in patients with macular degeneration
Investigators have determined that treating patients with an advanced form of age-related macular degeneration (AMD) with levodopa, a safe and readily available drug commonly used to treat Parkinson's disease, stabilized and improved their vision.
Combating drug resistance in age-related macular degeneration
An international team of researchers led by Baylor College of Medicine and Houston Methodist has discovered a strategy that can potentially address a major challenge to the current treatment for age-related macular degeneration,
Study finds unexpected suspect in age-related macular degeneration
Scientists have identified an unexpected player in the immune reaction gone awry that causes vision loss in patients with age-related macular degeneration (AMD), according to a new study published today in eLife.
Potential way to halt blinding macular degeneration identified
It would be the first treatment for dry age-related macular degeneration and could significantly improve treatment for wet AMD.
Heating techniques could improve treatment of macular degeneration
Age-related macular degeneration is the primary cause of central vision loss and results in the center of the visual field being blurred or fully blacked out.
Eye's vulnerability to macular degeneration revealed
Scientists have found significant differences in the shape and biology of the same type of cell taken from different parts of the retina, according to a study in eLife.
Hallucinations associated with brain hyperactivity in people with macular degeneration
New research from The University of Queensland has shown for the first time that visual hallucinations in people with macular degeneration are associated with abnormally heightened activity in the visual cortex of the brain.
Eating leafy greens could help prevent macular degeneration
A new study has shown that eating vegetable nitrates, found mainly in green leafy vegetables and beetroot, could help reduce your risk of developing early-stage age-related macular degeneration (AMD).
An orange a day keeps macular degeneration away: 15-year study
A new study has shown that people who regularly eat oranges are less likely to develop macular degeneration than people who do not eat oranges.
Macular degeneration linked to aging immune cells
Studying mice and cells from patients, vision researchers at Washington University School of Medicine in St.
More Macular Degeneration News and Macular Degeneration Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Warped Reality
False information on the internet makes it harder and harder to know what's true, and the consequences have been devastating. This hour, TED speakers explore ideas around technology and deception. Guests include law professor Danielle Citron, journalist Andrew Marantz, and computer scientist Joy Buolamwini.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at     You can read The Transition Integrity Project's report here.